Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Climb Bio presented initial Phase 1b data for budoprutug in immune thrombocytopenia (ITP) at the EHA Congress 2026, showing robust B-cell depletion and durable platelet responses. In the 250 mg cohort, four of six patients achieved durable responses, with mean platelet counts increasing by 111,000/µL at Week 24. Notably, three of four patients who had previously failed rituximab responded to budoprutug. The drug demonstrated a favorable safety profile with no serious adverse events or treatment discontinuations.
Key figures
- Drug Name
- budoprutug
- Phase Of Trial
- Phase 1b
- B cell depletion pct
- >90%
- Durable responses 250mg
- 4 out of 6
- Patients enrolled 250mg
- 6
- Patients enrolled 500mg
- 9
- Platelet increase 250mg
- 111,000 platelets/µL
- Total patients enrolled
- 15
- Rituximab failures responding
- 3 out of 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.